Literature DB >> 27560107

The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms.

M O Holmström1,2, C H Riley1, I M Svane2, H C Hasselbalch1, M H Andersen2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27560107     DOI： 10.1038/leu.2016.233

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN.

Authors:  S Jeromin; A Kohlmann; M Meggendorfer; S Schindela; K Perglerová; N Nadarajah; W Kern; C Haferlach; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2015-07-29       Impact factor: 11.528

Review 2.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

3.  Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.

Authors:  Ayalew Tefferi; Emnet A Wassie; Paola Guglielmelli; Naseema Gangat; Alem A Belachew; Terra L Lasho; Christy Finke; Rhett P Ketterling; Curtis A Hanson; Animesh Pardanani; Alexandra P Wolanskyj; Margherita Maffioli; Rosario Casalone; Annalisa Pacilli; Alessandro M Vannucchi; Francesco Passamonti
Journal:  Am J Hematol       Date:  2014-05-16       Impact factor: 10.047

Review 4.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

5.  Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.

Authors:  A Tefferi; T L Lasho; C Finke; A A Belachew; E A Wassie; R P Ketterling; C A Hanson; A Pardanani
Journal:  Leukemia       Date:  2014-02-26       Impact factor: 11.528

6.  Spontaneous immunity against Bcl-xL in cancer patients.

Authors:  Mads Hald Andersen; Sine Reker; Pia Kvistborg; Jürgen C Becker; Per thor Straten
Journal:  J Immunol       Date:  2005-08-15       Impact factor: 5.422

7.  Somatic mutations of calreticulin in myeloproliferative neoplasms.

Authors:  Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

8.  HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.

Authors:  Shamaila Munir; Gitte Holmen Andersen; Özcan Met; Marco Donia; Thomas Mørch Frøsig; Stine Kiaer Larsen; Tobias Wirenfeldt Klausen; Inge Marie Svane; Mads Hald Andersen
Journal:  Cancer Res       Date:  2013-01-17       Impact factor: 12.701

9.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.

Authors:  J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green
Journal:  N Engl J Med       Date:  2013-12-10       Impact factor: 91.245

10.  The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+ T cells.

Authors:  Shamaila Munir; Gitte Holmen Andersen; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2013-04-01       Impact factor: 8.110
View more
  31 in total

Review 1.  The Rationale for Immunotherapy in Myeloproliferative Neoplasms.

Authors:  Lucia Masarova; Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

Review 2.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

3.  Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms.

Authors:  Fiorella Schischlik; Roland Jäger; Felix Rosebrock; Eva Hug; Michael Schuster; Raimund Holly; Elisabeth Fuchs; Jelena D Milosevic Feenstra; Edith Bogner; Bettina Gisslinger; Martin Schalling; Elisa Rumi; Daniela Pietra; Gottfried Fischer; Ingrid Faé; Loan Vulliard; Jörg Menche; Torsten Haferlach; Manja Meggendorfer; Anna Stengel; Christoph Bock; Mario Cazzola; Heinz Gisslinger; Robert Kralovics
Journal:  Blood       Date:  2019-05-07       Impact factor: 22.113

4.  Neo-antigen specific memory T-cell responses in healthy individuals.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2019-04-19       Impact factor: 8.110

Review 5.  New Concepts of Treatment for Patients with Myelofibrosis.

Authors:  Prithviraj Bose; Mansour Alfayez; Srdan Verstovsek
Journal:  Curr Treat Options Oncol       Date:  2019-01-24

6.  The JAK2V617F and CALR exon 9 mutations are shared immunogenic neoantigens in hematological malignancy.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-08-02       Impact factor: 8.110

Review 7.  Unfolding the Role of Calreticulin in Myeloproliferative Neoplasm Pathogenesis.

Authors:  Ross L Levine; Elodie Pronier; Tiffany R Merlinsky
Journal:  Clin Cancer Res       Date:  2019-01-17       Impact factor: 12.531

Review 8.  Cancer immune therapy for myeloid malignancies: present and future.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch
Journal:  Semin Immunopathol       Date:  2018-07-09       Impact factor: 9.623

9.  Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response.

Authors:  Morten Orebo Holmström; Caroline Hasselbalch Riley; Vibe Skov; Inge Marie Svane; Hans Carl Hasselbalch; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2018-02-27       Impact factor: 8.110

10.  The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Authors:  M O Holmström; E Martinenaite; S M Ahmad; Ö Met; C Friese; L Kjær; C H Riley; P Thor Straten; I M Svane; H C Hasselbalch; M H Andersen
Journal:  Leukemia       Date:  2017-07-05       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.